INDIANAPOLIS — Eli Lilly Chief Executive David Ricks announced Tuesday that the company's GLP-1 medicines are working exactly as intended, confirming that nearly half a million newly eligible seniors are now efficiently routing federal healthcare spending straight to the firm's balance sheet.
Speaking on an early-morning earnings call, Ricks celebrated the sheer volume of elderly Americans who have begun serving as biological passthroughs for the U.S. treasury since expanded Medicare coverage launched in July. Of the 700,000 seniors who recently began taking weight-loss and diabetes injections, the CEO noted that a dominant 70 percent are currently using Lilly-branded compounds to move government capital into private equity portfolios.
We have successfully engineered a weekly injection that targets the exact metabolic pathways required to unlock the Medicare Part D trust fund.
Clinical data presented to investors showed that the medication is highly efficacious. Once administered, the GLP-1 receptor agonists reliably slow gastric emptying, suppress the patient's appetite, and autonomously trigger a $1,000-per-month recurring wire transfer from the Centers for Medicare & Medicaid Services directly to Indianapolis.
Following the call, the street immediately adjusted its guidance on the pharmaceutical sector. Analysts at BlackRock issued a note praising the logistical elegance of using the aging population as a middleman, calling it a significantly more stable revenue model than asking the federal government for a direct cash bailout.